4M Therapeutics Inc.
Princeton
About 4M Therapeutics Inc.
4M Therapeutics Inc. (4MTx) develops therapies for central nervous system (CNS) disorders with blockbuster potential. We focus on targets implicated in a wide array of disorders and indications. We apply unique insights from our living human brain cell platform, which was developed through a collaborative effort between Harvard, MIT, and the University of Washington) to identify and design more effective and safer therapeutics. The safety and efficacy of our lead compound, 4MT2001, have been demonstrated through in-human safety assessments and genetic target validation conducted by external researchers. These findings are further supported by our comprehensive in vitro and in vivo studies, which highlight its potential as a best-in-class treatment for bipolar disorder (BPD). BPD, a lifelong condition typically manifesting in the late teens to early 20s, affects approximately 7 million individuals in the U.S. The FDA has reviewed our program and provided feedback, enabling us to proceed with the initiation of Phase 1 clinical trials in early 2025. Our pipeline also includes potential breakthrough treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD), and other CNS disorders. We have raised over $5 million to date with all founders and board members participating.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $120.0K
- Funding stage: Seed
- Last round: Seed (Aug 2025)
- Website: 4mtx.net
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/4m-therapeutics-inc-124772 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.